Report: In big shift, medtech executives grow fonder of U.S. regulatory process
- Admin
- Apr 3, 2022
- 1 min read
By: Joel Berg
Executives used to lean toward European regulators launching their products in that region. But after a decade of change, they now see the U.S. as a better option. While the FDA gets kudos, the other issue remains challenging: reimbursement.
Comments